Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 19 entries
Sorted by: Best Match Show Resources per page
Development of an Enhanced Interprofessional Chief Resident Immersion Training (IP-CRIT) Program.

Gerontology & geriatrics education

Mohler J, D'Huyvetter K, O'Neill L, Clemens C, Waer A, Began V, Wendel C, Fain M.
PMID: 24191853
Gerontol Geriatr Educ. 2014;35(4):354-68. doi: 10.1080/02701960.2013.858331. Epub 2014 Jan 06.

Using interprofessional faculty, the authors reviewed and enhanced the nationally renowned Chief Resident Immersion Training (CRIT) in the Care of Older Adults Program to include Triple Aim objectives and interprofessional competency-based content and developed the Interprofessional CRIT. Evaluations were...

Cite
Mohler J, D'Huyvetter K, O'Neill L, et al. Development of an Enhanced Interprofessional Chief Resident Immersion Training (IP-CRIT) Program. Gerontol Geriatr Educ. 2014;35(4):354-68doi: 10.1080/02701960.2013.858331.
Mohler, J., D'Huyvetter, K., O'Neill, L., Clemens, C., Waer, A., Began, V., Wendel, C., & Fain, M. (2014). Development of an Enhanced Interprofessional Chief Resident Immersion Training (IP-CRIT) Program. Gerontology & geriatrics education, 35(4), 354-68. https://doi.org/10.1080/02701960.2013.858331
Mohler, Jane, et al. "Development of an Enhanced Interprofessional Chief Resident Immersion Training (IP-CRIT) Program." Gerontology & geriatrics education vol. 35,4 (2014): 354-68. doi: https://doi.org/10.1080/02701960.2013.858331
Mohler J, D'Huyvetter K, O'Neill L, Clemens C, Waer A, Began V, Wendel C, Fain M. Development of an Enhanced Interprofessional Chief Resident Immersion Training (IP-CRIT) Program. Gerontol Geriatr Educ. 2014;35(4):354-68. doi: 10.1080/02701960.2013.858331. Epub 2014 Jan 06. PMID: 24191853.
Copy Download .nbib Format: NLM
Automated Artifact Rejection Algorithms Harm P3 Speller Brain-Computer Interface Performance.

Brain computer interfaces (Abingdon, England)

Thompson DE, Mowla MR, Dhuyvetter KJ, Tillman JW, Huggins JE.
PMID: 34988241
Brain Comput Interfaces (Abingdon). 2019;6(4):141-148. doi: 10.1080/2326263X.2020.1734401. Epub 2020 Mar 02.

Brain-Computer Interfaces (BCIs) have been used to restore communication and control to people with severe paralysis. However, non-invasive BCIs based on electroencephalogram (EEG) are particularly vulnerable to noise artifacts. These artifacts, including electro-oculogram (EOG), can be orders of magnitude...

Cite
Thompson DE, Mowla MR, Dhuyvetter KJ, et al. Automated Artifact Rejection Algorithms Harm P3 Speller Brain-Computer Interface Performance. Brain Comput Interfaces (Abingdon). 2020;6(4):141-148doi: 10.1080/2326263X.2020.1734401.
Thompson, D. E., Mowla, M. R., Dhuyvetter, K. J., Tillman, J. W., & Huggins, J. E. (2019). Automated Artifact Rejection Algorithms Harm P3 Speller Brain-Computer Interface Performance. Brain computer interfaces (Abingdon, England), 6(4), 141-148. https://doi.org/10.1080/2326263X.2020.1734401
Thompson, David E, et al. "Automated Artifact Rejection Algorithms Harm P3 Speller Brain-Computer Interface Performance." Brain computer interfaces (Abingdon, England) vol. 6,4 (2019): 141-148. doi: https://doi.org/10.1080/2326263X.2020.1734401
Thompson DE, Mowla MR, Dhuyvetter KJ, Tillman JW, Huggins JE. Automated Artifact Rejection Algorithms Harm P3 Speller Brain-Computer Interface Performance. Brain Comput Interfaces (Abingdon). 2019;6(4):141-148. doi: 10.1080/2326263X.2020.1734401. Epub 2020 Mar 02. PMID: 34988241; PMCID: PMC8725686.
Copy Download .nbib Format: NLM
Effects of rumen-protected arginine supplementation and arginine-HCl injection on site and extent of digestion and small intestinal amino acid disappearance in forage-fed steers.

Translational animal science

Meyer AM, Klein SI, Kapphahn M, Dhuyvetter DV, Musser RE, Caton JS.
PMID: 32704704
Transl Anim Sci. 2018 Mar 08;2(2):205-215. doi: 10.1093/tas/txy007. eCollection 2018 Apr.

Four ruminally and intestinally cannulated steers were used in a 4 × 4 Latin square to evaluate effects of rumen-protected Arg supplementation or intravenous Arg injection on small intestinal delivery of AA, site and extent of digestion, and ruminal...

Cite
Meyer AM, Klein SI, Kapphahn M, et al. Effects of rumen-protected arginine supplementation and arginine-HCl injection on site and extent of digestion and small intestinal amino acid disappearance in forage-fed steers. Transl Anim Sci. 2018;2(2):205-215doi: 10.1093/tas/txy007.
Meyer, A. M., Klein, S. I., Kapphahn, M., Dhuyvetter, D. V., Musser, R. E., & Caton, J. S. (2018). Effects of rumen-protected arginine supplementation and arginine-HCl injection on site and extent of digestion and small intestinal amino acid disappearance in forage-fed steers. Translational animal science, 2(2), 205-215. https://doi.org/10.1093/tas/txy007
Meyer, Allison M, et al. "Effects of rumen-protected arginine supplementation and arginine-HCl injection on site and extent of digestion and small intestinal amino acid disappearance in forage-fed steers." Translational animal science vol. 2,2 (2018): 205-215. doi: https://doi.org/10.1093/tas/txy007
Meyer AM, Klein SI, Kapphahn M, Dhuyvetter DV, Musser RE, Caton JS. Effects of rumen-protected arginine supplementation and arginine-HCl injection on site and extent of digestion and small intestinal amino acid disappearance in forage-fed steers. Transl Anim Sci. 2018 Mar 08;2(2):205-215. doi: 10.1093/tas/txy007. eCollection 2018 Apr. PMID: 32704704; PMCID: PMC7200530.
Copy Download .nbib Format: NLM
Phase I Trial of .

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

D'Huyvetter M, Vos J, Caveliers V, Vaneycken I, Heemskerk J, Duhoux FP, Fontaine C, Vanhoeij M, Windhorst AD, Aa FV, Hendrikse NH, Eersels JLE, Everaert H, Gykiere P, Devoogdt N, Raes G, Lahoutte T, Keyaerts M.
PMID: 33277400
J Nucl Med. 2021 Aug 01;62(8):1097-1105. doi: 10.2967/jnumed.120.255679. Epub 2020 Dec 04.

No abstract available.

Cite
D'Huyvetter M, Vos J, Caveliers V, et al. Phase I Trial of . J Nucl Med. 2020;62(8):1097-1105doi: 10.2967/jnumed.120.255679.
D'Huyvetter, M., Vos, J., Caveliers, V., Vaneycken, I., Heemskerk, J., Duhoux, F. P., Fontaine, C., Vanhoeij, M., Windhorst, A. D., Aa, F. V., Hendrikse, N. H., Eersels, J. L. E., Everaert, H., Gykiere, P., Devoogdt, N., Raes, G., Lahoutte, T., & Keyaerts, M. (2021). Phase I Trial of . Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 62(8), 1097-1105. https://doi.org/10.2967/jnumed.120.255679
D'Huyvetter, Matthias, et al. "Phase I Trial of ." Journal of nuclear medicine : official publication, Society of Nuclear Medicine vol. 62,8 (2021): 1097-1105. doi: https://doi.org/10.2967/jnumed.120.255679
D'Huyvetter M, Vos J, Caveliers V, Vaneycken I, Heemskerk J, Duhoux FP, Fontaine C, Vanhoeij M, Windhorst AD, Aa FV, Hendrikse NH, Eersels JLE, Everaert H, Gykiere P, Devoogdt N, Raes G, Lahoutte T, Keyaerts M. Phase I Trial of . J Nucl Med. 2021 Aug 01;62(8):1097-1105. doi: 10.2967/jnumed.120.255679. Epub 2020 Dec 04. PMID: 33277400.
Copy Download .nbib Format: NLM
Automated Artifact Rejection Algorithms Harm P3 Speller Brain-Computer Interface Performance.

Brain computer interfaces (Abingdon, England)

Thompson DE, Mowla MR, Dhuyvetter KJ, Tillman JW, Huggins JE.
PMID: 34988241
Brain Comput Interfaces (Abingdon). 2019;6(4):141-148. doi: 10.1080/2326263X.2020.1734401. Epub 2020 Mar 02.

Brain-Computer Interfaces (BCIs) have been used to restore communication and control to people with severe paralysis. However, non-invasive BCIs based on electroencephalogram (EEG) are particularly vulnerable to noise artifacts. These artifacts, including electro-oculogram (EOG), can be orders of magnitude...

Cite
Thompson DE, Mowla MR, Dhuyvetter KJ, et al. Automated Artifact Rejection Algorithms Harm P3 Speller Brain-Computer Interface Performance. Brain Comput Interfaces (Abingdon). 2020;6(4):141-148doi: 10.1080/2326263X.2020.1734401.
Thompson, D. E., Mowla, M. R., Dhuyvetter, K. J., Tillman, J. W., & Huggins, J. E. (2019). Automated Artifact Rejection Algorithms Harm P3 Speller Brain-Computer Interface Performance. Brain computer interfaces (Abingdon, England), 6(4), 141-148. https://doi.org/10.1080/2326263X.2020.1734401
Thompson, David E, et al. "Automated Artifact Rejection Algorithms Harm P3 Speller Brain-Computer Interface Performance." Brain computer interfaces (Abingdon, England) vol. 6,4 (2019): 141-148. doi: https://doi.org/10.1080/2326263X.2020.1734401
Thompson DE, Mowla MR, Dhuyvetter KJ, Tillman JW, Huggins JE. Automated Artifact Rejection Algorithms Harm P3 Speller Brain-Computer Interface Performance. Brain Comput Interfaces (Abingdon). 2019;6(4):141-148. doi: 10.1080/2326263X.2020.1734401. Epub 2020 Mar 02. PMID: 34988241; PMCID: PMC8725686.
Copy Download .nbib Format: NLM
A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma.

Journal of hematology & oncology

Duray E, Lejeune M, Baron F, Beguin Y, Devoogdt N, Krasniqi A, Lauwers Y, Zhao YJ, D'Huyvetter M, Dumoulin M, Caers J.
PMID: 34727950
J Hematol Oncol. 2021 Nov 02;14(1):183. doi: 10.1186/s13045-021-01171-6.

BACKGROUND: Antibody-based therapies targeting CD38 are currently used as single agents as well as in combination regimens for multiple myeloma, a malignant plasma cell disorder. In this study, we aimed to develop anti-CD38 single-domain antibodies (sdAbs) that can be...

Cite
Duray E, Lejeune M, Baron F, et al. A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma. J Hematol Oncol. 2021;14(1):183doi: 10.1186/s13045-021-01171-6.
Duray, E., Lejeune, M., Baron, F., Beguin, Y., Devoogdt, N., Krasniqi, A., Lauwers, Y., Zhao, Y. J., D'Huyvetter, M., Dumoulin, M., & Caers, J. (2021). A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma. Journal of hematology & oncology, 14(1), 183. https://doi.org/10.1186/s13045-021-01171-6
Duray, Elodie, et al. "A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma." Journal of hematology & oncology vol. 14,1 (2021): 183. doi: https://doi.org/10.1186/s13045-021-01171-6
Duray E, Lejeune M, Baron F, Beguin Y, Devoogdt N, Krasniqi A, Lauwers Y, Zhao YJ, D'Huyvetter M, Dumoulin M, Caers J. A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma. J Hematol Oncol. 2021 Nov 02;14(1):183. doi: 10.1186/s13045-021-01171-6. PMID: 34727950; PMCID: PMC8561907.
Copy Download .nbib Format: NLM
JNJ-67569762, A 2-Aminotetrahydropyridine-Based Selective BACE1 Inhibitor Targeting the S3 Pocket: From Discovery to Clinical Candidate.

Journal of medicinal chemistry

Rombouts FJR, Kusakabe KI, Alexander R, Austin N, Borghys H, De Cleyn M, Dhuyvetter D, Gijsen HJM, Hrupka B, Jacobs T, Jerhaoui S, Lammens L, Leclercq L, Tsubone K, Ueno T, Morimoto K, Einaru S, Sumiyoshi H, Van den Bergh A, Vos A, Surkyn M, Teisman A, Moechars D.
PMID: 34553934
J Med Chem. 2021 Oct 14;64(19):14175-14191. doi: 10.1021/acs.jmedchem.1c00935. Epub 2021 Sep 23.

The discovery of a novel 2-aminotetrahydropyridine class of BACE1 inhibitors is described. Their pK

Cite
Rombouts FJR, Kusakabe KI, Alexander R, et al. JNJ-67569762, A 2-Aminotetrahydropyridine-Based Selective BACE1 Inhibitor Targeting the S3 Pocket: From Discovery to Clinical Candidate. J Med Chem. 2021;64(19):14175-14191doi: 10.1021/acs.jmedchem.1c00935.
Rombouts, F. J. R., Kusakabe, K. I., Alexander, R., Austin, N., Borghys, H., De Cleyn, M., Dhuyvetter, D., Gijsen, H. J. M., Hrupka, B., Jacobs, T., Jerhaoui, S., Lammens, L., Leclercq, L., Tsubone, K., Ueno, T., Morimoto, K., Einaru, S., Sumiyoshi, H., Van den Bergh, A., Vos, A., Surkyn, M., Teisman, A., & Moechars, D. (2021). JNJ-67569762, A 2-Aminotetrahydropyridine-Based Selective BACE1 Inhibitor Targeting the S3 Pocket: From Discovery to Clinical Candidate. Journal of medicinal chemistry, 64(19), 14175-14191. https://doi.org/10.1021/acs.jmedchem.1c00935
Rombouts, Frederik J R, et al. "JNJ-67569762, A 2-Aminotetrahydropyridine-Based Selective BACE1 Inhibitor Targeting the S3 Pocket: From Discovery to Clinical Candidate." Journal of medicinal chemistry vol. 64,19 (2021): 14175-14191. doi: https://doi.org/10.1021/acs.jmedchem.1c00935
Rombouts FJR, Kusakabe KI, Alexander R, Austin N, Borghys H, De Cleyn M, Dhuyvetter D, Gijsen HJM, Hrupka B, Jacobs T, Jerhaoui S, Lammens L, Leclercq L, Tsubone K, Ueno T, Morimoto K, Einaru S, Sumiyoshi H, Van den Bergh A, Vos A, Surkyn M, Teisman A, Moechars D. JNJ-67569762, A 2-Aminotetrahydropyridine-Based Selective BACE1 Inhibitor Targeting the S3 Pocket: From Discovery to Clinical Candidate. J Med Chem. 2021 Oct 14;64(19):14175-14191. doi: 10.1021/acs.jmedchem.1c00935. Epub 2021 Sep 23. PMID: 34553934.
Copy Download .nbib Format: NLM
Phase I Trial of .

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

D'Huyvetter M, Vos J, Caveliers V, Vaneycken I, Heemskerk J, Duhoux FP, Fontaine C, Vanhoeij M, Windhorst AD, Aa FV, Hendrikse NH, Eersels JLE, Everaert H, Gykiere P, Devoogdt N, Raes G, Lahoutte T, Keyaerts M.
PMID: 33277400
J Nucl Med. 2021 Aug 01;62(8):1097-1105. doi: 10.2967/jnumed.120.255679. Epub 2020 Dec 04.

No abstract available.

Cite
D'Huyvetter M, Vos J, Caveliers V, et al. Phase I Trial of . J Nucl Med. 2020;62(8):1097-1105doi: 10.2967/jnumed.120.255679.
D'Huyvetter, M., Vos, J., Caveliers, V., Vaneycken, I., Heemskerk, J., Duhoux, F. P., Fontaine, C., Vanhoeij, M., Windhorst, A. D., Aa, F. V., Hendrikse, N. H., Eersels, J. L. E., Everaert, H., Gykiere, P., Devoogdt, N., Raes, G., Lahoutte, T., & Keyaerts, M. (2021). Phase I Trial of . Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 62(8), 1097-1105. https://doi.org/10.2967/jnumed.120.255679
D'Huyvetter, Matthias, et al. "Phase I Trial of ." Journal of nuclear medicine : official publication, Society of Nuclear Medicine vol. 62,8 (2021): 1097-1105. doi: https://doi.org/10.2967/jnumed.120.255679
D'Huyvetter M, Vos J, Caveliers V, Vaneycken I, Heemskerk J, Duhoux FP, Fontaine C, Vanhoeij M, Windhorst AD, Aa FV, Hendrikse NH, Eersels JLE, Everaert H, Gykiere P, Devoogdt N, Raes G, Lahoutte T, Keyaerts M. Phase I Trial of . J Nucl Med. 2021 Aug 01;62(8):1097-1105. doi: 10.2967/jnumed.120.255679. Epub 2020 Dec 04. PMID: 33277400.
Copy Download .nbib Format: NLM
Correction to Optimization of 1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors Toward a Clinical Candidate.

Journal of medicinal chemistry

Gijsen HJM, Alonso de Diego SA, De Cleyn M, García-Molina A, Macdonald GJ, Martinez-Lamenca C, Oehlrich D, Prokopcova H, Rombouts FJR, Surkyn M, Trabanco AA, Van Brandt S, Van den Bossche D, Van Gool M, Austin N, Borghys H, Dhuyvetter D, Urmaliya V, Teisman A, Moechars D.
PMID: 30525600
J Med Chem. 2018 Dec 27;61(24):11415. doi: 10.1021/acs.jmedchem.8b01859. Epub 2018 Dec 07.

No abstract available.

Cite
Gijsen HJM, Alonso de Diego SA, De Cleyn M, et al. Correction to Optimization of 1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors Toward a Clinical Candidate. J Med Chem. 2018;61(24):11415doi: 10.1021/acs.jmedchem.8b01859.
Gijsen, H. J. M., Alonso de Diego, S. A., De Cleyn, M., García-Molina, A., Macdonald, G. J., Martinez-Lamenca, C., Oehlrich, D., Prokopcova, H., Rombouts, F. J. R., Surkyn, M., Trabanco, A. A., Van Brandt, S., Van den Bossche, D., Van Gool, M., Austin, N., Borghys, H., Dhuyvetter, D., Urmaliya, V., Teisman, A., & Moechars, D. (2018). Correction to Optimization of 1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors Toward a Clinical Candidate. Journal of medicinal chemistry, 61(24), 11415. https://doi.org/10.1021/acs.jmedchem.8b01859
Gijsen, Harrie J M, et al. "Correction to Optimization of 1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors Toward a Clinical Candidate." Journal of medicinal chemistry vol. 61,24 (2018): 11415. doi: https://doi.org/10.1021/acs.jmedchem.8b01859
Gijsen HJM, Alonso de Diego SA, De Cleyn M, García-Molina A, Macdonald GJ, Martinez-Lamenca C, Oehlrich D, Prokopcova H, Rombouts FJR, Surkyn M, Trabanco AA, Van Brandt S, Van den Bossche D, Van Gool M, Austin N, Borghys H, Dhuyvetter D, Urmaliya V, Teisman A, Moechars D. Correction to Optimization of 1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors Toward a Clinical Candidate. J Med Chem. 2018 Dec 27;61(24):11415. doi: 10.1021/acs.jmedchem.8b01859. Epub 2018 Dec 07. PMID: 30525600.
Copy Download .nbib Format: NLM
Beyond the Barrier: Targeted Radionuclide Therapy in Brain Tumors and Metastases.

Pharmaceutics

Puttemans J, Lahoutte T, D'Huyvetter M, Devoogdt N.
PMID: 31374991
Pharmaceutics. 2019 Aug 01;11(8). doi: 10.3390/pharmaceutics11080376.

Brain tumors are notoriously difficult to treat. The blood-brain barrier provides a sanctuary site where residual and metastatic cancer cells can evade most therapeutic modalities. The delicate nature of the brain further complicates the decision of eliminating as much...

Cite
Puttemans J, Lahoutte T, D'Huyvetter M, et al. Beyond the Barrier: Targeted Radionuclide Therapy in Brain Tumors and Metastases. Pharmaceutics. 2019;11(8)doi: 10.3390/pharmaceutics11080376.
Puttemans, J., Lahoutte, T., D'Huyvetter, M., & Devoogdt, N. (2019). Beyond the Barrier: Targeted Radionuclide Therapy in Brain Tumors and Metastases. Pharmaceutics, 11(8), . https://doi.org/10.3390/pharmaceutics11080376
Puttemans, Janik, et al. "Beyond the Barrier: Targeted Radionuclide Therapy in Brain Tumors and Metastases." Pharmaceutics vol. 11,8 (2019). doi: https://doi.org/10.3390/pharmaceutics11080376
Puttemans J, Lahoutte T, D'Huyvetter M, Devoogdt N. Beyond the Barrier: Targeted Radionuclide Therapy in Brain Tumors and Metastases. Pharmaceutics. 2019 Aug 01;11(8). doi: 10.3390/pharmaceutics11080376. PMID: 31374991; PMCID: PMC6723032.
Copy Download .nbib Format: NLM
Preclinical Targeted α- and β.

Cancers

Puttemans J, Dekempeneer Y, Eersels JL, Hanssens H, Debie P, Keyaerts M, Windhorst AD, van der Aa F, Lecocq Q, Breckpot K, Morgenstern A, Bruchertseifer F, Lahoutte T, Devoogdt N, D'Huyvetter M.
PMID: 32326199
Cancers (Basel). 2020 Apr 21;12(4). doi: 10.3390/cancers12041017.

HER2-targeted therapies have drastically improved the outcome for breast cancer patients. However, when metastasis to the brain is involved, current strategies fail to hold up to the same promise. Camelid single-domain antibody-fragments (sdAbs) have been demonstrated to possess favorable...

Cite
Puttemans J, Dekempeneer Y, Eersels JL, et al. Preclinical Targeted α- and β. Cancers (Basel). 2020;12(4)doi: 10.3390/cancers12041017.
Puttemans, J., Dekempeneer, Y., Eersels, J. L., Hanssens, H., Debie, P., Keyaerts, M., Windhorst, A. D., van der Aa, F., Lecocq, Q., Breckpot, K., Morgenstern, A., Bruchertseifer, F., Lahoutte, T., Devoogdt, N., & D'Huyvetter, M. (2020). Preclinical Targeted α- and β. Cancers, 12(4), . https://doi.org/10.3390/cancers12041017
Puttemans, Janik, et al. "Preclinical Targeted α- and β." Cancers vol. 12,4 (2020). doi: https://doi.org/10.3390/cancers12041017
Puttemans J, Dekempeneer Y, Eersels JL, Hanssens H, Debie P, Keyaerts M, Windhorst AD, van der Aa F, Lecocq Q, Breckpot K, Morgenstern A, Bruchertseifer F, Lahoutte T, Devoogdt N, D'Huyvetter M. Preclinical Targeted α- and β. Cancers (Basel). 2020 Apr 21;12(4). doi: 10.3390/cancers12041017. PMID: 32326199; PMCID: PMC7226418.
Copy Download .nbib Format: NLM
The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy.

Molecular cancer therapeutics

Puttemans J, Stijlemans B, Keyaerts M, Vander Meeren S, Renmans W, Fostier K, Debie P, Hanssens H, Rodak M, Pruszynski M, De Veirman K, Vanderkerken K, Lahoutte T, Morgenstern A, Bruchertseifer F, Devoogdt N, D'Huyvetter M.
PMID: 34667109
Mol Cancer Ther. 2021 Oct 19; doi: 10.1158/1535-7163.MCT-21-0220. Epub 2021 Oct 19.

To this day, multiple myeloma remains an incurable cancer. For many patients, recurrence is unavoidably a result of lacking treatment options in the minimal residual disease stage. This is due to residual and treatment-resistant myeloma cells that can cause...

Cite
Puttemans J, Stijlemans B, Keyaerts M, et al. The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy. Mol Cancer Ther. 2021;doi: 10.1158/1535-7163.MCT-21-0220.
Puttemans, J., Stijlemans, B., Keyaerts, M., Vander Meeren, S., Renmans, W., Fostier, K., Debie, P., Hanssens, H., Rodak, M., Pruszynski, M., De Veirman, K., Vanderkerken, K., Lahoutte, T., Morgenstern, A., Bruchertseifer, F., Devoogdt, N., & D'Huyvetter, M. (2021). The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy. Molecular cancer therapeutics, . https://doi.org/10.1158/1535-7163.MCT-21-0220
Puttemans, Janik, et al. "The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy." Molecular cancer therapeutics vol. (2021). doi: https://doi.org/10.1158/1535-7163.MCT-21-0220
Puttemans J, Stijlemans B, Keyaerts M, Vander Meeren S, Renmans W, Fostier K, Debie P, Hanssens H, Rodak M, Pruszynski M, De Veirman K, Vanderkerken K, Lahoutte T, Morgenstern A, Bruchertseifer F, Devoogdt N, D'Huyvetter M. The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy. Mol Cancer Ther. 2021 Oct 19; doi: 10.1158/1535-7163.MCT-21-0220. Epub 2021 Oct 19. PMID: 34667109.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 19 entries